{"id":1366,"date":"2026-08-18T14:33:55","date_gmt":"2026-08-18T14:33:55","guid":{"rendered":"https:\/\/www.faastpharmacy.com\/blog\/?p=1366"},"modified":"2026-08-18T14:40:29","modified_gmt":"2026-08-18T14:40:29","slug":"avexitide-post-bariatric-hypoglycemia","status":"publish","type":"post","link":"https:\/\/www.faastpharmacy.com\/blog\/avexitide-post-bariatric-hypoglycemia","title":{"rendered":"Avexitide Reduced Hypoglycemia After Bariatric Surgery"},"content":{"rendered":"

Avexitide Reduced Blood Sugar Crashes After Gastric Bypass\u2014But It Works Nothing Like Ozempic<\/h1>\n

Imagine going through gastric bypass, losing a large amount of weight, and finally getting your blood sugar under control. Then, months or years later, meals start causing a completely different problem.<\/p>\n

You eat breakfast and feel fine. An hour later, your hands begin to shake. You are sweating even though the room is cool. Someone asks you a simple question, but you cannot quite put an answer together.<\/p>\n

At first, you may blame the coffee. Or stress. Or assume you waited too long to eat.<\/p>\n

Then it happens again.<\/p>\n

For some people who have undergone gastric bypass, blood sugar does not merely settle back down after a meal. It drops hard. In severe cases, the person may become confused, lose consciousness, or have a seizure.<\/p>\n

There has never been an FDA-approved medicine specifically for this problem. That is why the latest news about avexitide is getting attention.<\/p>\n

On August 18, Amylyx Pharmaceuticals announced results from a Phase 3 trial involving 78 adults with post-bariatric hypoglycemia. Participants who received avexitide once a day had 55% fewer serious low-blood-sugar episodes than those who received placebo during the 16-week study.<\/p>\n

The headline is likely to confuse anyone familiar with Ozempic or Wegovy. Avexitide is described as a drug that acts on the GLP-1 pathway, but it is not another injection intended to help people lose weight.<\/p>\n

In fact, it does almost the opposite of what Ozempic does.<\/p>\n

Ozempic activates the GLP-1 receptor. Avexitide blocks it.<\/p>\n

Why would anyone want to block GLP-1 after weight-loss surgery? Because in people with post-bariatric hypoglycemia, the body may be responding too strongly to meals. The intestine releases a large burst of GLP-1, the pancreas answers with too much insulin, and blood sugar crashes a couple of hours later.<\/p>\n

Avexitide is meant to calm that response before the crash happens.<\/p>\n

For a patient who has become afraid to drive after lunch or leave home without emergency glucose, cutting serious episodes by more than half could make everyday life feel considerably safer.<\/p>\n

There are still reasons not to get ahead of the evidence. This was a small trial. We have the company\u2019s main announcement, but not yet a full medical paper that allows outside experts to examine every detail. Avexitide is also still experimental. You cannot walk into a pharmacy today and fill a prescription for it.<\/p>\n

Even so, this is more than an early laboratory finding. It is a successful Phase 3 result for a condition that has no approved medication of its own.<\/p>\n

What is post-bariatric hypoglycemia?<\/h2>\n

Most people understand gastric bypass in fairly simple terms: the surgeon makes the stomach smaller, so the patient eats less.<\/p>\n

That is true, but it leaves out a large part of the story.<\/p>\n

Roux-en-Y gastric bypass also changes the route food takes through the digestive system. A small pouch is created from the stomach and connected to a lower section of the small intestine. Food now skips most of the stomach and the first part of the intestine.<\/p>\n

The body notices that change.<\/p>\n

A meal that once moved gradually through the stomach can now reach the intestine very quickly. Sugar and other carbohydrates are absorbed faster, and the intestine releases a powerful wave of hormones to help deal with the incoming food.<\/p>\n

One of those hormones is GLP-1.<\/p>\n

GLP-1 tells the pancreas that glucose is arriving and that insulin is needed. Normally, this is a useful and carefully timed response. Insulin moves glucose out of the bloodstream and into cells, where it can be used for energy.<\/p>\n

But in someone with post-bariatric hypoglycemia, the response can overshoot.<\/p>\n

Take a breakfast such as sweet cereal, toast, or juice. Glucose rises quickly. GLP-1 surges. The pancreas sends out a large amount of insulin. By the time that insulin has done its job, it has done too much of it.<\/p>\n

Blood sugar falls below the level the body needs.<\/p>\n

The strange part is that this usually does not happen while the person is eating. They may finish breakfast, clean the kitchen, and leave for work feeling completely normal. The trouble begins one to three hours later.<\/p>\n

A woman might be halfway through a supermarket when she suddenly feels shaky and drenched in sweat. A man may finish lunch, get into his car, and realize at a traffic light that he cannot focus properly. Someone else may be sitting in a meeting when the conversation stops making sense.<\/p>\n

The early signs can look like ordinary hunger or anxiety. Your heart starts beating faster. You feel weak, nervous, or light-headed. Concentration becomes difficult. There may be an urgent feeling that you need to eat something immediately.<\/p>\n

Many people deal with the first few episodes by grabbing juice, candy, or whatever carbohydrate is nearby. The symptoms improve, so they assume the problem is solved.<\/p>\n

Then it happens again.<\/p>\n

When blood sugar falls far enough, the brain begins running short of glucose. At that point, the person may stop behaving like themselves. Speech becomes confused. Coordination disappears. They may not recognize that they need help.<\/p>\n

Some people faint. Others experience seizures.<\/p>\n

After one severe episode, life can become much smaller. Driving feels risky. Eating alone feels risky. A restaurant meal becomes difficult because the patient does not know exactly how much sugar or starch is in the food. Even going for a walk after lunch may require glucose tablets, a monitor, and a plan for what to do if symptoms begin.<\/p>\n

That is what makes post-bariatric hypoglycemia different from feeling hungry before dinner. It is not simply an inconvenience or a sign that someone should snack more often. It is a genuine metabolic complication that can interfere with work, travel, exercise, and a person\u2019s ability to be safely left alone.<\/p>\n

Why can bariatric surgery cause low blood sugar?<\/h2>\n

GLP-1 is normally useful.<\/p>\n

The intestine releases it after food arrives. GLP-1 tells the pancreas to produce insulin when glucose is present, slows stomach emptying, and helps the brain recognize fullness. These effects explain why medications that activate the GLP-1 receptor can be useful for diabetes and weight management.<\/p>\n

Roux-en-Y gastric bypass changes the timing.<\/p>\n

Food reaches the lower intestine unusually quickly, creating a much larger GLP-1 response than would normally occur after the same meal. In people with PBH, the pancreas can then release an excessive amount of insulin.<\/p>\n

Glucose initially climbs. Insulin arrives in force. Then glucose drops below the safe range.<\/p>\n

Not everyone who has bariatric surgery develops this problem. Many people experience no clinically significant hypoglycemia at all. Among those who do, the severity also varies. Some can manage symptoms by changing how they eat; others continue to have unpredictable events despite careful planning.<\/p>\n

Amylyx estimates that PBH affects approximately 8% of Americans who have undergone bariatric surgery. Exact prevalence is difficult to establish because studies use different definitions, some patients do not recognize their symptoms, and continuous glucose monitors may detect low readings that never produce noticeable impairment.<\/p>\n

What is clear is that severe PBH can take over daily life.<\/p>\n

Someone who has lost consciousness once may stop driving. A person who became confused at work may begin eating defensively throughout the day. Others carry emergency carbohydrates everywhere and still feel unsafe being alone.<\/p>\n

The operation that improved one part of their health has created another problem nobody expected.<\/p>\n

How does avexitide work?<\/h2>\n

This is the part many headlines blur.<\/p>\n

Ozempic and Wegovy contain semaglutide, which activates the GLP-1 receptor. Mounjaro and Zepbound contain tirzepatide, which activates both GLP-1 and GIP receptors. These medicines are agonists: they turn particular receptor signals on.<\/p>\n

Avexitide is an antagonist. It blocks the GLP-1 receptor.<\/p>\n

That difference is not small. It is the entire idea behind the drug.<\/p>\n

After a meal, a person with PBH may release an exaggerated amount of GLP-1. Avexitide is designed to prevent some of that signal from reaching GLP-1 receptors on insulin-producing pancreatic beta cells. With less GLP-1 activity, the pancreas should release less insulin, reducing the chance of a severe glucose crash.<\/p>\n

So although avexitide belongs in a conversation about the GLP-1 pathway, calling it a \u201cGLP-1 weight-loss drug\u201d would be misleading.<\/p>\n

Readers interested in the agonist side of this drug class can review how a new oral GLP-1 weight-loss pill<\/a> differs from injectable treatments. Avexitide is being developed for a different disease and produces the opposite effect at the receptor.<\/p>\n

\"Diagram<\/div>\n
<\/div>\n
What did the Phase 3 trial find?<\/span><\/div>\n

LUCIDITY was a randomized, double-blind, placebo-controlled Phase 3 trial conducted at 21 sites in the United States.<\/p>\n

The study enrolled 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Participants were assigned in a three-to-two ratio to receive either 90 mg of avexitide or placebo by subcutaneous injection once daily.<\/p>\n

The double-blind treatment period lasted 16 weeks.<\/p>\n

Researchers measured the combined rate of Level 2 and Level 3 hypoglycemic events:<\/p>\n